Clinical trial
Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory…
NCT00193232 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193232 |
|---|---|
| Title | Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer |
| Official title | A Phase II Trial of Weekly Docetaxel and Bortezomib (Velcade; PS-341) in the Treatment of Patients With Advanced Hormone-Refractory Prostate Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Aventis Pharmaceuticals Industry Millennium Pharmaceuticals, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Docetaxel, Bortezomib |
| Enrollment | 50 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2005 |
| Completion | Feb 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jul 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: